Vaccines 6
COVID-19 Vaccines: Stories of monopoly, blackmail and inequality
COVID-19 Vaccines: Stories of monopoly, blackmail and inequality
By Randy Alonso Falcón, Cuban journalist, Director of the web portal Cubadebate, the site Fidel Soldado de las Ideas and the Cuban Television program “Mesa Redonda”. He directed other Cuban publications such as Somos Jóvenes, Alma Mater and Juventud Técnica. He received the Juan Gualberto Gómez National Journalism Award in TV in 2018. He has won several awards in the 26th of July National Journalism Contest. Email: director@cubadebate.cu On Twitter: @RandyAlonsoFalc,
Edilberto Carmona Tamayo, Chief of the Department of Multimedia Production, Monitoring and Innovation of Cubadebate and the Roundtable. Graduated in Journalism in 2016 from the University of Holguín. Contact: edilberto@cubadebate.cu On Twitter: @edctamayo
March 19, 2020
Translated and edited by Walter Lippmann for CubaNews.
Design: Edilberto Carmona Tamayo
The apprehensions raised in some countries by the AstraZeneca/Oxford vaccine, the US dirty campaign against the Russian Sputnik V and the confirmed refusal of the most powerful nations to let their pharmaceutical companies temporarily release the patents of their antidotes against COVID-19, have further strained the availability of vaccines and deepened the profound differences in the right to life between the powerful and the poor in this world.
Never before has a health emergency struck so many in so many places and in such a short space of time. COVID-19 has already affected more than 120 million people in the world and has caused the death of more than 2.6 million human beings.
Such a universal challenge warranted a global and coordinated response. But once again, contrary to the demands of the UN and the World Health Organization, nationalism, pettiness, the overwhelming power of transnational corporations and every person for themselves, have prevailed.
Vaccines seem to be the only effective barriers against the pandemic. Only immunization of a majority of the world’s population could put a stop to the growing transmission of the SARS-CoV-2 virus. But neither the pharmaceutical transnationals nor the governments of the rich world have that vocation for collective response and global solidarity.
Who can develop and produce vaccines?
The pharmaceutical and biotechnology industry suffers from high concentration and transnationalization. Large companies from developed countries and emerging economies monopolize drug research, production and distribution. Nine of them are among the 100 companies that generate the highest revenues worldwide.
According to Euromonitor Global, the pharmaceutical industry is responsible for almost 4% of global production activity. If it were a country, it would be among the 15 richest economies on the planet. Almost half of the sector’s total sales come from China and the USA, followed by Switzerland, Japan, Germany and France.
The production of vaccines, in particular, concentrates in 4 large firms more than 80% of the market, according to 2019 data: the British GlaxoSmithKline, the American Merck Sharp & Dohme and Pfizer, and the French Sanofi.
That global market generated in 2018 some $37 billion and it is estimated that by 2027 it will exceed 6$4.5 billion.
As is remarkable, underdeveloped nations -which are the vast majority-, have hardly any capacity to develop their own vaccines (Cuba is one of the few honorable exceptions) and no productive capacities of their own. This has left them with little room for maneuver to influence the uneven development of vaccines in the midst of the pandemic.
How have the vaccines against COVID-19 been financed?
Since the WHO declared COVID-19 a pandemic on March 11, it has been calling for a concerted and joint solution to the threat. But the wrathful logic of the market dictates the course of our world and what has taken place since then is a frantic race to hit the bull’s eye (immune and financial), in which there has been no shortage of obstacles, pressures and even blackmail.
From the outset, the major powers allied themselves with the major pharmaceutical corporations in order to conveniently manage the discovery of a solution that would allow them to emerge with an advantage from the health and economic crisis ravaging the world.
Governments provided at least $8.6 billion for vaccine development, according to analyst firm Airfinity. The US, EU and UK invested billions in AstraZeneca’s vaccine, developed by Oxford University. Germany invested $445 million in the vaccine developed by Pfizer and its German partner, BioNTech. Moderna’s vaccine was fully funded and co-produced by the U.S. government.
While philanthropic organizations contributed $1.9 billion. Individual personalities such as Bill Gates, Alibaba founder Jack Ma and country music star Dolly Parton made contributions.
Only $3.4 billion has come from the pharma companies’ own investment, part of which has also come from external funding.
Despite the fact that Big Pharma has only provided one third of the funding, who is reaping the economic benefits? Who has set the rules of the game in the distribution of vaccines?
Foul Play
To obtain the vaccine against COVID became, beyond the health interest, a geopolitical objective. Whoever managed to get the vaccine would capitalize on its commoditization and whoever had more financial resources would be able to monopolize more immunizations.
Scandalous was the news of the Trump administration’s maneuver, as early as March 2020, for the German company CureVac -which had begun to research a possible vaccine-, to leave its headquarters in the European country and move to the U.S. in exchange for “large amounts of money”.
As it had also acquired PCR tests, pulmonary ventilators, masks and biosafety equipment, Washington also set out from the beginning to acquire the production and distribution of vaccines.
This was coupled with sometimes subtle, sometimes overt, smear campaigns against Russian and Chinese vaccine candidates in a concerted attempt to shut them out of other markets. Many doubts were cast on the speed of development, quality of clinical trials and effectiveness of the candidates from both nations, especially against Sputnik V from Gamaleya Laboratories.
A nurse prepares a Sputnik V injection at a Moscow clinic. Photo: AFP
After Russia’s leading vaccine was certified by its authorities and sparked interest in several nations, the United States and the European Union have been tripping it up all over the place. The 2020 Annual Report of the U.S. Department of Health and Human Services (HHS) recently revealed that the U.S. Department of Health and Human Services (HHS) recently revealed that the Office of Global Affairs (OGA) used the Office of the Health Attaché in Brazil to persuade the government of that South American country to “reject the Russian COVID-19 vaccine”.
Text subtitled as Combating malign influences in the Americas. Photo Screenshot of HSS annual report
In response to the revelation, Russian presidential spokesman Dimity Peskov stated: “In many countries, the scale of pressure is unprecedented (…) such selfish attempts to force countries to abandon some vaccines lack perspective. We believe that there should be as many doses of vaccines as possible so that all countries, including the poorest, have a chance to stop the pandemic.”
The European Union, for its part, has not yet given the green light to the Russian vaccine for use in its member countries, even though that region has lagged behind the US, Canada, the UK and Israel in vaccine availability, and even though the prestigious health journal The Lancet acknowledged the high efficacy of Sputnik V in a publication.
Beyond such barriers, Russian and Chinese vaccines have been gaining ground in different regions, due to their effectiveness and the global shortage of immunizers. Slovakia even left the European Union fold to acquire 2 million doses of Sputnik V and Hungary, which has also approved the use of the Russian vaccine, acquired doses of the Chinese Sinopharm, which has also not received the green light from the European Medicines Agency.
Health workers in Indonesia unload a shipment of Chinese vaccine Sinovac
Blackmail without anesthesia
The States made the major investment, but BigPharma imposes the conditions and keeps the revenues. The monopoly of a few multinationals in the procurement and production of anti-COVID-19 vaccines gives such companies overwhelming power.
Recent reports show how pharmaceutical giant Pfizer has attempted to impose onerous conditions on Latin American nations to supply them with certain quantities of its injectable.
Brazilian President Jair Bolsonaro showed his displeasure these days at Pfizer’s demands on his government, pointing out that among the conditions set by the consortium is a clause in the purchase contract that exempts it from “all liability” for possible side effects of its immunizer.
“We have been very hard and they have been very hard on us. They won’t change a comma. The government is dealing with this together with Congress and it is being discussed in terms of a relaxation of the law”, said the recently dismissed Brazilian Minister of Health, Army General Eduardo Pazuello.
Argentina, Peru and the Dominican Republic also suffered intense pressure from Pfizer, as shown in an investigation by The Bureau Investigative Journalism.
Pfizer representatives in Buenos Aires demanded indemnification against any civil claims citizens might file if they experienced adverse effects after being vaccinated. “We offered to pay for millions of doses upfront, we accepted this international insurance, but the last request was extraordinary: Pfizer demanded that Argentina’s sovereign assets also be part of the legal backing,” an Argentine official confessed. “It was an extreme demand that I had only heard when the foreign debt had to be negotiated, but in that case as in this one, we rejected it immediately.”
The Argentine government believes that Pfizer’s demands were part of a commercial strategy that favored sales to developed countries and not to Latin American countries.
There are several voices that warn that the urgency to have vaccines available for a disease that has left so many dead in the world may have led some governments to accept significant limitations on their responsibilities and demand transparency on the agreements with pharmaceutical companies.
Professor Lawrence Gostin, director of the World Health Organization’s Collaborating Center for National and Global Health Law said, “Pharmaceutical companies should not use their power to limit life-saving vaccines in low- and middle-income countries” and noted that liability protection should not be used as “the sword of Damocles hanging over the heads of desperate countries with desperate populations”.
Even mighty Europe seems to have felt the pressures. Although EU agreements with vaccine manufacturers are kept with their main clauses secret, the Vaccine Procurement Strategy made public by the European Commission states that “the responsibility for the development and use of the vaccine, including any specific compensation required, will lie with the procuring Member States.”
Excerpt from the contract for the purchase of vaccines from CureVac by the European Commission was disclosed with all essential parts blacked out.
Who will be able to be vaccinated in 2021?
Vaccine production capacities in the world are insufficient to have the necessary doses this year to immunize the world’s population. The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) says that the estimated global demand for vaccines in 2021 is between 10 and 14 billion doses.
According to statistics cited by data firm Statista, the United States can produce nearly 4.7 billion doses of COVID-19 vaccine and India more than 3 billion potential doses. China, previously not a major player in the vaccine export market, has committed to manufacturing more than 1 billion doses.
Great Britain, Russia, Germany and South Korea are also among the established manufacturing centers, but with lower production capacity.
Vacuna Johnson & Johnson. Photo: Reuters.
Given this reality, the inequity and injustice of today’s world are once again evident: the richest countries have purchased most of the vaccines that will be produced in 2021 (even for stockpiling), while poor nations will not have doses to administer even to their most vulnerable segments of the population. More than 100 nations are waiting for the first bulb to arrive.
It is estimated that 90% of the inhabitants of the nearly 70 lowest-income countries will not have the opportunity to be vaccinated against COVID-19 this year.
The most powerful nations took advantage of their purchasing power and investments in vaccine development to secure supplies of the coveted antidote.
So far, about 12.7 billion doses of various coronavirus vaccines have been pre-purchased, enough to vaccinate approximately 6.6 billion people (except for Johnson & Johnson’s, all vaccines approved so far require two doses).
More than half of those doses, 4.2 billion insured, with the option to buy another 2.5 billion, have been purchased by wealthy countries that are home to only 1.2 billion people.
Canada has bought enough doses to inoculate every Canadian five times, while the U.S., U.K., EU, EU, Australia, New Zealand and Chile have bought enough to vaccinate their citizens at least twice, although some of the vaccines have not yet been approved.
Israel struck a deal for 10 million doses and a promise of a steady supply from Pfizer in exchange for data on vaccine recipients. According to reports, the country also paid $30 per dose, double the price paid by the EU.
As Irene Bernal, a researcher on access to medicines at the NGO Salud por Derecho, told the newspaper El País last December, “we are seeing that whoever has the money is the one who has the access. We have kept 53% of the vaccines for 14% of the population, the rich. And the companies have a limited production capacity, so when are the doses going to reach the poorest countries?”
Design: Edilberto Carmona tamayo
Low- and middle-income countries, with 84% of the world’s population, have made deals directly with pharmaceutical companies, but have so far secured only 32% of the supply.
“We are in such a massive crisis,” said Fatima Hassan, founder of the South African Health Justice Initiative. “If even in South Africa we can’t vaccinate half our population soon, I can’t even imagine how Zimbabwe, Lesotho, Namibia and the rest of Africa will cope. If this is going to go on for another three years, we won’t get any kind of continental or global immunity.”
Mexican President Andres Manuel Lopez Obrador and his Foreign Minister Marcelo Ebrard have asked the U.S. authorities to allow them to acquire part of the tens of millions of AstraZeneca vaccines produced in the United States, which Washington has stockpiled without having approved the use of this drug. Other countries that have already authorized this vaccine are begging to have them.
Mexico, one of the countries with the largest presence of COVID-19, has so far administered some 4.4 million doses using Pfizer, AstraZeneca, Sinovac and Sputnik V vaccines, in a population of more than 128 million inhabitants, which means a low vaccination rate, according to the website www.ourworldindata.org managed by the University of Oxford.
The most current statistics from this observatory show the low proportion and unequal distribution of the number of fully vaccinated people (with all the necessary doses) in the world:
Percentage of population fully vaccinated with required doses by country, March 16, 2021. Graphic: OurWorldinData /Oxford University
According to data collected by Bloomberg, as of Thursday, more than 410 million doses of anti-COVID vaccines have been administered worldwide in some 132 countries. This represents just 2.7% of the world’s population.
| % of population | |||||
|---|---|---|---|---|---|
| Country | Doses administered | Enough for % of people | given 1+ dose | fully vaccinated | Daily rate of doses administered |
| Global Total | 410,697,435 | – | – | – | 9,959,983 |
| U.S. | 115,730,008 | 17.7 | 22.7 | 12.3 | 2,503,731 |
| China | 64,980,000 | 2.3 | – | – | 960,000 |
| EU | 54,084,195 | 6.1 | 8.3 | 3.6 | 1,236,527 |
| India | 38,920,259 | 1.4 | 2.3 | 0.5 | 1,835,249 |
| U.K. | 27,614,526 | 20.7 | 38.5 | 2.8 | 458,471 |
| Brazil | 14,936,060 | 3.6 | 5.2 | 1.9 | 357,115 |
| Turkey | 12,707,210 | 7.6 | 9.6 | 5.7 | 306,998 |
| Germany | 10,067,955 | 6.1 | 8.4 | 3.7 | 233,813 |
| Israel | 9,609,766 | 53.1 | 57.1 | 49.1 | 76,526 |
| Russia | 8,500,000 | 2.9 | 3.4 | 2.4 | 100,000 |
| France | 7,927,771 | 6.1 | 8.7 | 3.5 | 214,391 |
| Chile | 7,907,275 | 20.7 | 27.9 | 13.5 | 290,378 |
| Italy | 7,330,104 | 6.1 | 8.4 | 3.8 | 178,874 |
| UAE | 6,980,466 | 32.5 | – | – | 81,874 |
| Indonesia | 6,787,283 | 1.3 | 1.8 | 0.7 | 256,516 |
| Morocco | 6,499,476 | 9.1 | 12.0 | 6.3 | 199,542 |
| Spain | 5,993,363 | 6.4 | 8.8 | 4.1 | 117,322 |
| Poland | 4,738,902 | 6.2 | 8.1 | 4.4 | 72,826 |
| Mexico | 4,737,622 | 1.9 | 3.2 | 0.5 | 178,501 |
Vaccine Apartheid
Design: Edilberto Carmona Tamayo
Scientists and activists warn that we are heading towards a “vaccine apartheid” in which people in the global South will be vaccinated years later than those in the West.
Not only will poorer countries be forced to wait, but many are already being charged much higher prices per dose. Uganda, for example, has announced a deal for millions of vaccines from AstraZeneca, at a price of $7 a dose, more than three times what the European Union paid for it. Including transport fees, it will cost $17 to fully vaccinate a Ugandan.
The effects of this inequity would be severe. A model developed by Northeastern University indicates that if the first 2 billion doses of Covid-19 vaccines were distributed proportionally by national population, deaths worldwide would be reduced by 61%. But if the doses are monopolized by 47 of the world’s richest countries, only 33% fewer people would be saved.
Scientists are also concerned that if there are countries that will not be able to immunize a large part of the population, there will be more opportunities for the virus to continue mutating and deaths will increase in these under-vaccinated countries, making the available vaccines less effective over time.
As WHO Director-General Dr. Tedros Adhanom Ghebreyesus noted earlier this year, “…we face a real danger that, while vaccines bring hope to some, they become one more brick in the wall of inequality between those who have resources and those who do not.”
A restrained alternative
The difficulty in securing vaccine supply will make many poorer countries dependent on Covax, an organization created in April 2020, coordinated by WHO, the Coalition for Innovations in Epidemic Preparedness and GAVI, the international vaccine alliance.
Covax aims to administer 2 billion doses globally, including at least 1.3 billion for 92 low- and middle-income countries, by the end of 2021. This would be enough to inoculate 20% of each country’s population, with priority given to healthcare workers, the elderly and people with underlying medical conditions, although that target has been criticized as inadequate to deal with the pandemic.
Analysts estimate instead that Covax will at most provide between 650 million and 950 million doses, divided among 145 nations, including some of those with enough confirmed agreements for the vaccines to vaccinate their citizens multiple times such as Canada and New Zealand.
The pharmaceuticals have not delivered on their promises to COVAX and AstraZeneca, which was the main supplier is also facing its own particular situation of millions of doses withheld in the US and Europe.
Even Europe is not spared from the backlog
Germany suspended vaccination with AstraZeneca as of Monday 15. Photo: EPA Even the European Union is frustrated by the obstacles they have encountered in vaccinating their population. The only European vaccine so far, the AstraZeneca/Oxford vaccine, is in serious trouble after reports of some 30 cases of clotting problems in people immunized with the injectable. There are already 13 EU countries that have suspended vaccination with AstaZeneca, despite the fact that the WHO and the European regulatory agency defend its use as having more benefits than harmful impact.
To make matters worse, in the midst of the flare-up in the region, AstraZeneca had only delivered 25% of the agreed doses to the EU for the first quarter and Pfizer was also behind in its deliveries. In early 2021 Italy threatened to sue Pfizer for reducing by 29% the distribution of doses in that country. Now the European Commission announces that it has reached an agreement with Pfizer/BioNTech to bring forward 10 million doses for the second quarter of the year.
Despite the fact that BioNtech and CureVac are German, this European country has had problems with vaccination. The daily Der Spiegel pointed out a few weeks ago that “the European Union and Germany could run short of vaccine supplies. The delay in signing contracts with pharmaceutical companies could mean that the vaccines arrive late, as well as not being sufficient”.
The EU has so far administered 11 doses per 100 people, compared with 33 doses in the US and 39 doses in the UK, according to the Bloomberg Vaccine Tracker index.
The low availability and unequal distribution within the European Union has led countries such as Austria, Bulgaria, Czech Republic, Croatia and Latvia to publicly express their discomfort and ask for a “correction” in the distribution.
In view of the dilemma, the European Commission determined that the pharmaceutical companies which have vaccine factories in EU territories will not be able to export the products they generate to other regions if they do not receive permission to take them out of the country from the authorities of those nations.
Already on March 4, Italy, one of the countries hardest hit by the pandemic, took advantage of this EU decision to ban the export to Australia of 250,000 doses of Astrazeneca’s vaccine, which the Anglo-Swedish pharmaceutical company produced at its factory in Agnani, near Rome.
As frustrations grow more intense, some European officials are blaming the United States and the United Kingdom. European Council President Charles Michel said the U.S., along with Britain, “have imposed a total ban on the export of vaccines or vaccine components that are produced on their territory.”
Asked about this, Jen Psaki, the White House press secretary, told reporters that vaccine manufacturers were free to export their U.S.-made products as long as they met the terms of their contracts with the [U.S.] government.
But because AstraZeneca’s vaccine was produced with help from the Defense Production Act, for which it received more than $1 billion in funding, Biden has to approve overseas shipments of its doses.
No holds barred for a round deal
The most powerful countries have put pharmaceutical profits above global immunity, despite political discourse that there will be no solution to the pandemic unless it is corralled worldwide.
Last week, on the same day marking one year since WHO declared COVID-19 a pandemic, the US, EU, UK and Canada (all with sufficient vaccines secured) blocked the latest attempt by poor or middle-income nations to speed access to vaccines and treatments for COVID-19 by temporarily lifting World Trade Organization rules protecting intellectual property.
A resolution sponsored by South Africa and India and backed by 57 countries, which called for suspending during the pandemic parts of the TRIPS (Trade Related Protections for Intellectual Property Rights) Agreement that protects medical patents, was rejected by the bloc of rich nations. It had already met the same fate in discussions at the WTO in October and December 2020.
An agreement would have allowed underdeveloped or emerging nations to produce COVID drugs and vaccines without waiting for or adhering to licensing agreements with pharmaceutical companies that own the intellectual property of these medical products. This would have expanded the production of antidotes against the lethal disease and lowered treatment costs.
The governments of wealthy nations, the majority financiers of the anti-COVID vaccines, based their refusal on concerns that the release of intellectual property, even temporarily, could reduce incentives for corporate research and also questioned whether “developing” nations could begin production of the drugs soon enough to prevent the spread of the virus.
The truth is that Big Pharma multinationals were initially reluctant to fund COVID vaccine research because of the uncertainty of a race against time to get results and because of the poor cost-effectiveness of creating vaccines for health emergencies in the past.
The drugs sought by these companies are primarily those offered to citizens of wealthy countries, and especially those needed for chronic diseases requiring routine doses, which make them highly profitable.
But after they have seen the profitability that the durability in time of COVID-19 can leave them, they do not want now any limit to the “party” of income that they are enjoying in view of the urgent demand for vaccines.
Moderna reported that it has signed advance purchase agreements for more than US$18 billion for supplies to be delivered this year, while Pfizer projected nearly US$15 billion in revenues this year for its vaccine with BioNTech.
Boxes containing Modern COVID-19 vaccine are prepared for shipment at McKesson’s distribution center in Olive Branch, Mississippi, U.S., Dec. 20, 2020. Photo: Reuters
The main vaccine developers have benefited from billions of dollars in public subsidies, yet pharmaceutical companies have been granted a monopoly over their production, as well as over the profits they generate.
The prices at which vaccines are sold to different countries (they vary) are kept under the veil of secrecy of the agreements signed between pharmaceutical companies and governments, although the specialized website Statista has calculated the average price per dose at these amounts:
Multiply those numbers by the billions of doses required every x years (depending on the length of time these vaccines achieve immunity) and you can calculate how much the dance of the millions will amount to.
But, while pharmaceutical companies profit and control the pace and scope of vaccinations, the costs of the unequal distribution of vaccines to the global economy could be as high as $9 billion, according to Katie Gallogly-Swan, a researcher working with the United Nations Conference on Trade and Development (UNCTAD).
“It is unconscionable that in the midst of a global health crisis, huge multi-billion dollar pharmaceutical companies continue to prioritize profits, protect their monopolies and raise prices, instead of prioritizing the lives of people everywhere, including the Global South, U.S. Senator Bernie Sanders aptly tweeted a few days ago.
“The world is on the brink of a catastrophic moral failure” has written the Director-General of the World Health Organization. Meanwhile, over here, we cross our fingers for Soberana and Abdala to immunize all of us, without distinction, before this year expires.
Cuba to immunize its entire population
Cuba will be among the first countries to immunize its entire population.
Speaking at the Round Table space, the president of BioCubaFarma said that the vaccine production and distribution capacities have already been analyzed and organized for their programming until next December, once the studies of the four vaccine candidates yield the expected satisfactory results.
Published: Thursday 04 February 2021 | 11:43:53 pm.
Author: Ana Maria Dominguez Cruz
Translated and edited by Walter Lippmann for CubaNews.
Cuba develops four vaccine candidates against COVID-19.
The confidence that Cuba will be one of the first countries that will be able to immunize its entire population from its existing capacities of production and distribution of vaccines against COVID-19 came this Thursday at the Round Table, dedicated to the subject.
Eduardo Martínez Díaz, president of BioCubaFarma, explained this while speaking on the radio-TV program, together with Marta Ayala Ávila, general director of the Center for Genetic Engineering and Biotechnology; Vicente Vérez Bencomo, general director of the Finlay Institute of Vaccines, and Eduardo Ojito Magaz, general director of the Center for Molecular Immunology.
Likewise, Mr. Martínez Díaz pointed out that they have already been analyzed and organized for their programming until next December, once the studies of the four vaccine candidates yield the expected satisfactory results.
He said that our scientists are working on four vaccine candidates at the same time because they all use the same type of antigen, so that the desired immune response can be achieved in all cases.
In addition, he explained that all the genetic information has been inserted in bacteria, yeast and cells of higher organisms, such as mammals, and that in the latest variants encouraging results were achieved which allowed advancing in that direction. Each one will differentiate the formulation of the vaccines, based on platforms used in previous vaccines with marked effectiveness and safety.
The President of BioCubaFarma said that “the vaccines are working well”, but we still cannot say that they are effective, “that is why we have to continue with the studies. We cannot bet on a variant and then the studies not give the expected results. In that case, we would have to start all over again”.
He emphasized that the production of several vaccines could be deployed at the same time, in case the expected results were obtained in all of them, and then the doses would be studied, according to each population group, as well as the possibility of assigning some of them to the treatment of COVID-19 convalescents.
He pointed out that, as an advantage, Cuban vaccines do not require large refrigeration chains, but temperatures of two to eight degrees Celsius. In addition, they allow for the application of successive booster doses, which is essential in view of the appearance of new variants of the virus.
Martinez Diaz insisted that it is not possible to acquire vaccines produced by other countries because there is not enough quantity to do so. “To date, only 108 million doses have been applied, which means that only a little more than one percent of the population has been vaccinated. Only 13 countries have applied more than one million doses of vaccine, including the United States and China.”
He stressed the need for an increase in the global vaccination rate and for prices to fall, so that the entire population has the possibility of protecting itself, including those living in poor countries.
COMMENTS ON WEB PAGE (Unedited):
Jorge Puerto
Friday 05 February 2021 | 07:42:28 am.
Encouraging news.
Reply
Valo
Friday 05 February 2021 | 08:22:45 am.
Bravo for Cuba. congratulations to all Cuban scientists.
Reply
Neosan72
Friday 05 February 2021 | 09:58:48 am.
The incorrect headline should read CUBA will vaccinate 100 percent of the population at the conclusion of clinical trials because you dare to anticipate events without having an idea of the effectiveness of the current vaccine projects It is very easy to write without delving into the matter and violate international procedures this can steal much credibility to the work of all scientists of our nation and I’m sure you do not have the information on the percentage of effectiveness and immunological load generated by such vaccine candidates.
Reply
Leo
Friday 05 February 2021 | 12:59:33 pm.
Hi all. I believe and trust in Cuban science and also in the managers and scientists who are in charge. If they say so it is because they know. My congratulations and hopefully they will be ready and only when they should be, not in a hurry. Greetings, Leo
Reply
neisicruz
Friday 05 February 2021 | 02:43:30 pm.
I trust in Cuban medicine, in our scientists, in the Revolution. Thank you for the effort you make every day.
Reply
Zuleika machado gomez
Friday 05 February 2021 | 06:30:39 pm.
I would like to congratulate the collective of scientists as always putting their intellect and dedication in favor of the health of our people. Let’s hope that our people continue to comply with the measures because unfortunately there are many irresponsible people who discard the established measures putting at risk their health and that of others. Without thinking that there are so many people involved in this fight who spend many days away from their families the medical and paramedical personnel who are on the front line to the cooks nurses drivers etc who are also working and can be infected who have families . To them our most sincere respect. And to the scientists of this important project a thousand blessings. And our immense gratitude . ????????????????????????????????????????????????????????????????????????????????♥️♥️♥️♥️
Reply
Nery Pila
Friday 05 February 2021 | 11:11:21 pm.
The universal desire to be able to have the certainty of being vaccinated efficiently and effectively against Covid is immediate, but the certainty of Cuban scientists that we will have our population and who knows how many more internationally as usual is firm and certain. Congratulations to our scientists. I trust
Reply
Ariel
Saturday 06 February 2021 | 11:21:25 am.
Israel has already vaccinated 80 ? of its population and for free, Cuba may vaccinate its entire population but still can not be given time, we must first confirm the results of their vaccines. Let’s not be sensationalist, let’s stick to reality, so that we don’t see previous campaigns on various issues that later are not fulfilled.
Reply
Raider
Saturday 06 February 2021 | 12:46:17 pm.
Since we will be among the first who will be the other nations at the top of that list and with which vaccines have they procured vaccination?
Cuban vaccine engineering
Vaccines and sovereignty (IV)
Cuban vaccine engineering
By Luis A. Montero Cabrera
January 28, 2021
This is the fourth in a series of articles
Translated and edited by Walter Lippmann for CubaNews.
Cuba is rapidly developing four vaccine projects against coronavirus. Photo: Ahora.
It has been news in Cuba for months that we are generating our vaccines from platforms already created. The centers generating such projects work in partnership, exchanging experiences and knowledge, and also competing, as it should be done in a society that works for the good of all. Any group that participates will be happy for the triumph of the other, because what matters is the welfare of the whole society. Obviously they will also be very happy if their own vaccine candidate is successful.
It has been mentioned that our vaccines are all based on a key antigen of the COVID 19 virus: the constituent molecules of the outer spikes of the aggregate that makes up the virus. This molecular complex is referred to as RBD, from the acronym for receptor binding domain. We have also learned that adjuvants are substances that increase the effectiveness of vaccines. Their use is a common practice of this “engineering”, even to achieve vaccines against several diseases simultaneously.
The Finlay Vaccine Institute (IFV) is an institution that has grown from the success in the 80’s of the last century with the world’s first vaccine against meningococcus B. The current management has another very important success under its belt, in this case from the University of Havana (UH), with the world’s first commercial synthetic vaccine. This was put into practice at the beginning of this century against haempphilus influenzae. IFV is now working on at least two vaccine candidates known as SOBERANA 01 and SOBERANA 02. The RBD antigens of both are chemically treated variants of the coronavirus spikes.
The SOBERANA 01 antigen is based on the RBD produced from live mammalian cells into which DNA has been introduced with the codes to make them produce the desired molecules. This is why it is called “recombinant” RBD. The great advantage is that these molecules are identical to those of the virus but have been obtained without the intervention of this harmful entity and in a very efficient and harmless way in our industrial plants for this purpose in the neighboring Center for Molecular Immunology (CIM). The latter has a long experience in these matters and a proverbial willingness to empower itself through collaboration.
The RBD has been transformed with highly advanced laboratory chemical methods to duplicate it in a single structure. This is a so-called “dimeric” form that in preliminary tests proved to be more stimulating to the immune system. In short, it is more immunogenic than the simple “monomeric” form.
SOBERANA 01 also contains proteins that are harmless antigens of the outer membrane of the dreaded meningococcus bacteria in conjunction with aluminum hydroxide as adjuvants. The meningococcal antigen helps to “trigger” the generation of antibodies. Aluminum hydroxide is harmless, but it prolongs the presence of the antigen and gives our defenses more time to react. The interest in the effectiveness of a vaccine lies in the fact that it causes us to generate antibodies (immunogenicity) and that these are the ones that trigger the defense actions against COVID 19 (specific immunogenicity).
The SOBERANA 02 antigen is the same RBD of the COVID 19 virus but in monomeric form. The aim is to provoke the immune response of the organism by conjugating it (molecularly binding it) with another well-known and harmless antigen as adjuvant: the “tetanus toxoid”. This substance is associated with the bacteria that produce tetanus, but is chemically inactivated to render it harmless. It has long been used as their highly effective vaccine. A construction of the RBD with the toxoid creates a complex containing more specific antigens. It can be said that it would be “multimeric”. Thus an interesting engineering of the antigen with an adjuvant ensues.
The Center for Genetic Engineering and Biotechnology (CIGB), one of the most important institutions in Cuban science, has generated the other vaccines. Its track record is transcendental in these matters. It has two candidates also based on the RBD antigen whose coded name is CIGB 669 for nasal application and CIGB 66 for intramuscular application. Their applications have “combat” names such as MAMBISA and ABDALA. The mambisas were the women who joined the forces of the liberating army against the peninsular crown at the end of the 19th century. This denomination was reviled and even pejorative in the Spanish royalist press of the time. They made it equivalent to something like “terrorist” today. However, when the forces of freedom triumphed, it became a symbol of sublime militancy. ABDALA is the name of a play in poetry by José Martí, his first and adolescent literary work. The hero Abdala appears as a young man who is a convinced defender of his homeland, who puts it before all other personal and family interests. Our vaccines are samples of sovereignty, the fight for freedom and love for the homeland.
The nasal formulation of the preparation CIGB 669 takes advantage of the excellent permeability capacity of the intranasal membranes. Most of our skin is shielded against the penetration of molecules of any kind. But nasal membranes are not like that. They encompass a large surface area that is very dense in blood vessels and very permeable, which makes them a very attractive route for medicating. This pathway is also naturally selected to generate some very neutralizing antibodies and in the same location that is the route of virus entry.
Its RBD is accompanied as an adjuvant with another antigen that is used in the proven “HeberNasvac”, the chronic hepatitis B vaccine that is also administered nasally. This is its nucleocapsid, which is what the central molecular complex in a virus particle is called. Viruses are not cells, but they usually have this kind of “nucleus”. HeberNasvac” is the world’s first therapeutic vaccine against a chronic infectious disease. This platform is patented by CIGB for its vaccines. In the world there is only one other nasal vaccine on the market, the FluMist and Fluenz Tetra (according to their applications in the USA and Europe) and it is used against influenza. It has the advantages of being non-invasive and can be applied even in precarious hygienic conditions, as can be the case in many places in this disparate world.
Unlike the Finlay Vaccine Institute vaccines, the adjuvant nucleocapsid in CIGB 669 is recombinant and is produced in a typical culture medium. Its RBD, also recombinant, from CIGB is produced in yeast. MAMBISA is actually a procedure consisting of dose combinations of the two CIGB vaccine candidates. ABDALA is intramuscular only with the CIGB 66 candidate.
The success of a vaccine as a drug needs to be demonstrated before mass application. How is the most indicated and effective one known? How is work being done to test Cuban vaccines in times when a single day’s delay in application can cost a life?
Luis Alberto Cabrera Montero holds a Doctorate Chemical Sciences. He is a Senior Researcher and Full Professor at the University of Havana. He is President of the Scientific Advisory Council of the University of Havana and is a Merit Member and Coordinator of Natural and Exact Sciences of the Academy of Sciences of Cuba. For a full biography, see http://www.academiaciencias.cu/en/node/674
The Antigen of Cuban Vaccines
Vaccines and Sovereignty (III)
The Antigen of Cuban Vaccines Against Covid-19
By Luis A Montero Cabrera
January 21, 2021
Translated by Merriam Ansara for CubaNews and other outlets.
This is the third in a series of articles.
The application of the Cuban Sovereign vaccine candidate begins. Photo: Ismael Francisco/ Cubadebate.
We Cubans have a very remarkable platform for biomedical production, one might even say extraordinary for a country like ours. An infamous 2004 document from the “Commission for the Support of a Free Cuba” of a previous administration in the US described it as unnecessary and very expensive for such a poor country as ours: “Large sums were also directed to activities such as the development of biotechnology and bioscience centers not appropriate in magnitude and expense for such a fundamentally poor nation, and which have failed to be justified financially”. The only thing to be added to this is that those of us in the South with darker skin ought not to have the luxury of science. But our biopharmaceutical sector is the child of necessity, of the creative initiative of a lover of knowledge and a true revolutionary, as was our Fidel, and of an educational policy that gives everybody without distinction the right to reach the highest level of human knowledge and to with that knowledge, create. It was not begun with a specific strategy or goal but became, as it is today a bastion of the knowledge, science and culture of our country. It was and is the fruit of revolutionary thinking.
The development of a vaccine today requires the existence of today’s conditions for this kind of research. It must begin by looking at the scientific literature for antecedents and ways of doing things that can lead to the implementation of more and more exquisite laboratory procedures and rigorous tests. In our case and for the above reasons, a firm base for the research was already established when the COVID 19 emergency arose. Events such as these cannot be foreseen, but the preparation of the conditions to face them is the duty of any decent political system.
Chinese science immediately made available to the international community everything it knew about this dangerous and ultra-contagious virus and in other countries as well the information that was being generated was made available to all. Under these conditions, several of our scientific groups set to work to obtain a specific Cuban vaccine for this disease. One of the efforts, at the Finlay Vaccine Institute, is led by the same Prof. Vicente Vérez who obtained the previous milestone of the vaccine against “Haemophilus influenzae”, the first with synthetic antigens that was used and commercialized in the world. The other groups involved work at the Center for Genetic Engineering and Biotechnology with a long tradition also in the design and production of novel vaccines.
Remember that the essential component of a vaccine is the antigen that activates the immune system and leaves it ready to fight and destroy the foreign invader. Additional determining factors are both the adjuvants and the pharmaceutical forms for delivering the vaccine to humans. If you have an established and strong foundation in these last two aspects, determining the most suitable antigen becomes the heart of the creative work.
The antigen chosen in Cuba, for many reasons, was the “receptor-binding domain” of the virus (RBD). In simple terms, these are the molecules that constitute the external “spikes” so striking that they appear in the pictorial representation and the high-resolution microscopy of the viral molecular aggregate. This CoV “spike” protein (S) plays the most important role in viral binding, fusion and entry into cells of the organism attacked by the virus.
Therefore, it serves as a target for the immune system to develop antibodies, and for scientists to use them as antigens in the design of effective vaccines. An article that appeared in one of the branches of the well-known journal Nature had characterized this component as very promising as a vaccine antigen against COVID 19 as early as March 2020. The authors of the article are a very good reflection of the current internationalization of the basic sciences. Most are Chinese in origin and did extensive work in collaboration between the Lindsley F. Kimball Research Institute in New York, the Beijing Institute of Microbiology and Epidemiology, and the Key Laboratory for Medical Molecular Virology at Fudan University in Shanghai.
Our compañeros evaluated alternatives. One of them was to generate the so-called messenger RNA that was capable of producing the antigen in human cells. It is an ultra-modern technology that is being used in some of the COVID 19 vaccines that are already being applied. It has some advantages, but also has an important disadvantage so far not overcome for a vaccine that is intended to be administered massively throughout the world, especially the less developed one: it requires very strict cooling conditions for its transport and preservation.
Our biotechnology system, on the other hand, has at the Center for Molecular Immunology (CIM) the possibility to “ferment” mammalian cells that directly produce the RBD antigen, since the technology has been developed for other similar productions. It also has the possibility of producing a significant quantity if the antigen is viable for our vaccine. Therefore, all Cuban vaccine candidates, at least up to now, are based on this antigen, with some modification that makes it more active.
The results are exhilarating. And thus our scientists began the race to produce a variety of vaccines, in different institutions and by different scientific groups, collaborating and competing, in order to arrive at the best solutions. “SOBERANAS” 1 and 2, the MAMBISA and the ABDALA are very promising.
Vaccines are drugs. Therefore, they require measurements of their effectiveness, knowing their contraindications and risks, and finding the appropriate formulations and the most viable forms of administration before applying them en masse. Everything must proceed in a strict regulatory framework to ensure that consequences more serious than the disease itself were avoided. If they have the same antigen, how are our vaccine variants different? What state are they in their research and development?
Havana, January 20, 2021
Luis Alberto Cabrera Montero holds a Doctorate Chemical Sciences. He is Senior Researcher and Full Professor at the University of Havana. He is President of the Scientific Advisory Council of the University of Havana and is a Merit Member and Coordinator of Natural and Exact Sciences of the Academy of Sciences of Cuba. For a full biography, see http://www.academiaciencias.cu/en/node/674
What are vaccines?
Vaccines and Sovereignty (II):
What are Vaccines?
By Luis A Montero Cabrera
January 11, 2021
Translated by Merriam Ansara for CubaNews and other outlets.
This is the second in a series of articles.
Seventy coronavirus vaccines are in development worldwide, and three are already being tested in human trials, the World Health Organization said. Photo: iStock
The molecules of an invading biological entity that are identified and are accessible to the human immune system are often referred to as “antigens”. They are usually expressed in the outermost parts of the nanoscopic carrier and are a necessary part of its composition. They are the same when found in a virus, in a fungus, in a bacterium, or in the cells of an organ from another being transplanted into our body.
An important characteristic of the infection and self-healing process is that when an individual overcomes a disease by the action of the immune system, it usually remains prepared to defeat it in future reinfections of the same type. The system “remembers” the intruder antigen and thus we are prepared to reject its carriers again. It is a biological fabric very refined by natural selection through many generations and species.
By realizing this, and using scientific reasoning, human beings try to use this defense “memory” to ensure that people do not get sick with an infection, even if they have never suffered from the disease. It is about “teaching” the immune system of each individual to activate and destroy any morbid invasion once its antigens are detected. The challenge is great, because to invade the body with antigens from a certain infection without making the person sick requires wise processing.
The result is known as a “vaccine.” Its name is due to the fact that the first formulations were cultivated in cows. It is always a chemical-biological preparation of antigens to achieve active acquired immunity against a particular infectious disease. The first vaccines contained the organisms that caused the disease from weakened or dead forms of themselves. It was not known then that what the immune system recognized was only its antigens. These preparations thus “taught” the human body to “shoot” the actions that would destroy the invader. Vaccines can be prophylactic when they prevent and prevent the effects of future infection, as it is desired that COVID-19 be, or therapeutic when they are used to fight a disease that has already invaded the body, such as cancer.
Most likely, the first disease to be prevented by inoculation was smallpox. It seems that the first recorded use of it occurred in the 16th century in China. The scientific and reproducible vaccine against smallpox was invented and duly reported in the specialized literature in 1796 by the English physician Edward Jenner. Smallpox was a contagious and deadly disease, and it is said to kill up to 60% of infected adults and 80% of children.
Tomas Romay y Chacón was a physician and scientist born in Havana in 1764. Having begun by studying law he switched to medicine and in 1791 at the age of 27 was 33rd medical graduate in Cuba. He became a professor at our University of Havana and co-founder of the Royal Patriotic Society of Havana, today the Economic Society of Friends of the Country. As early as 1804, just 8 years after the appearance of the vaccine in Europe, Romay implemented smallpox vaccination on our island with preparations made “in situ” with the support of the Patriotic Society. In this way, he used the local science instead of waiting for delayed arrival of the vaccine from the Metropolis. He and his collaborators followed the procedures published and described by Jenner and manufactured the first Cuban vaccine, the smallpox vaccine. A marvelous success of a nascent, Creole, nation’s innovation and wisdom.
Time passed and scientific research led to the knowledge that the key to vaccines were the antigens and not the entire infectious entities.
Vaccines have been produced in Cuba for many decades. Two of them at least have been both original and exclusive. In 1987 Drs. Concepción Campa and Gustavo Sierra led a scientific group at the Finlay Vaccine Institute to obtain a vaccine that at that time was the first of its kind in the world. This vaccine was and still is very effective against a bacterium that attacks the meninges in the brain and nervous system, called group B and C meningococcus. This type of meningitis is particularly deadly in children. Cuban science at the University of Havana produced in 2004 the world’s first efficient commercial vaccine based on an antigen manufactured in the laboratory, that is, “synthetic”. Prof. Vicente Vérez, a scientist who has dedicated his life to the chemistry of sugars, his wife Dr. Violeta Fernández (who died very young) and their collaborators were the authors of this second great feat. Thanks to the work of these scientific groups, many Cuban children and children in many parts of the world are alive and active today as adults.
Vaccines don’t just contain antigens. The immune system is not equally effective in all people and at all ages. Certain antigens are more activating than others because they are more easily recognized and “trigger” the work of the entire system that feels invaded. Vaccines are made more effective with so-called “adjuvants” (helpers) which, when given together with the appropriate antigens, cause many people’s immune systems to wake up more quickly and efficiently.
New types of vaccines have recently appeared that do not contain antigens directly but rather RNA that allows our cells to synthesize them “in situ”, recognize them and learn to fight them. While the vaccines that contain only antigens without the need to supply the infectious agent are efficient and safe, these others are as well and furthermore allow for mutations of the virus to be taken into account with much greater facility and so ensure the utility of the vaccines over time.
It can be said that vaccines are pieces of biological technology that represent a lifeline for many human beings. Without them we would be at the mercy of Darwinian natural selection and an epidemic would be survived only by the few who could overcome it thanks to some singularity of their organism. This was the case before science intervened by inventing vaccines. The cost was immense in precious lives ending early. It could also be said that without vaccines some type of infection could come along that might lead to the extinction of homo sapiens as a living species, which has happened many times before with other species in the beautiful and harsh history of life on this planet.
And what will the current vaccines against COVID and very particularly the SOBERANAS, MAMBISA and ABDALA be like? How do you prove that they serve what they have been designed for?
Havana, January 6, 2021
Luis Alberto Cabrera Montero holds a Doctorate Chemical Sciences. He is a Senior Researcher and Full Professor at the University of Havana. He is President of the Scientific Advisory Council of the University of Havana and is a Merit Member and Coordinator of Natural and Exact Sciences of the Academy of Sciences of Cuba. For a full biography, see http://www.academiaciencias.cu/en/node/674
The virus and the immune system
Vaccines and Sovereignty (I):
The virus and the immune system
By Luis A Montero Cabrera
December 31, 2020
Translated by Merriam Ansara for CubaNews and other outlets.
This is the first in a series of articles.
A vial of COVID-19 vaccine from Pfizer and BioNTech, Boston, Massachusetts, USA, on December 16, 2020. Illustrative image: Craig F. Walker/Pool / Reuters
The word we all speak today with hope is “vaccine.” We have had an absolutely extraordinary 2020’s year. An unexpected and unprecedented pandemic has changed everything, in almost every way for the worse, although there also have been some good consequences. The political defeat of some enemies of our country who did not even know how to lead their powerful country in these extraordinary conditions may have been influenced by this factor, and that is a good consequence. That and the vaccines, four of them Cuban, mean a more optimistic outlook for 2021 for us. Unfortunately, those who lalready lost or will lose their lives to this pandemic will not be able to take advantage of what little good there is in the remains of this pandemic.
We already know how life originates, how it works and how it manipulates the laws of the rest of the universe to perpetuate itself, more as a system than in its individualities. Within that system of life, viruses appear at a given moment and have their own space. The one that has caused the current pandemic is only one of the many that exist and that have existed, and it will by no means be the last that affects humanity and other living beings. They can arise anywhere and will or will not spread depending on their characteristics and how science influences where they occur.
Molecules are inanimate particles of the nanoworld since their sizes are around one billionth of a meter. Some of them act as the “bricks” and “cement” that make up living organisms. There are many types of molecules that are part of this network and the most unique and complex are proteins (which are the ones that “work” and are also part of the functional structures), fats (which “cement” and store energy), sugars (which cement and hold, but in a much more specialized way, and also accumulate and transport energy), and the so-called “nucleic acids”. The latter are very special and complex molecules whose fundamental function is to accumulate the information of the living system so that all the others can exist.
Viruses are not living beings, but relatively stable aggregates or associations of various types of vital molecules, the fundamental component of which are nucleic acids. In this case, they carry their own information, but foreign to the system of other living organisms. However, they include the ability to self-replicate at the expense of the animal or plant, including us, in which they are housed. They change (or mutate) in the environment in which they develop and out of the many ways in which this happens, the vast majority fail. However, the few mutations that turn out to be successful put the cells they invade at their service to give rise to new viruses. And in that task, it always affects in one way or another the host cell that lent it its resources. If the virus is COVID-19, it seems to affect the cell to such an extent and in such a way that even the ways we defend ourselves against them can kill us.
There is a great debate among virologists about the origin of viruses. Three main hypotheses are usually mentioned: i) The “progressive” hypothesis that states that viruses arose from genes (made up of nucleic acids) in cells that showed the ability to move or transfer to other cells; ii) the “regressive” hypothesis proposes that viruses are genetic remains of dead cell organisms that showed the ability to be assimilated by other living cells and to reproduce there; and iii) the “primary virus” hypothesis proposes that viruses precede cells in evolution: they would have appeared first. For this reason, they may have been the initiating molecular aggregates of the ability to self-reproduce. If this is the correct hypothesis, it would make them predecessors of cells and in conditions of “coevolution” with them, which are their current hosts.
A living system such as the human being that has evolved in the last 3.7 billion years has very efficient ways to defend itself against potentially harmful agents that are carriers of foreign molecules. We do this through what is known as the “immune system.” This has a complex form of action, which can be understood in a simplified way.
The immune system of our body recognizes the vital molecular structures that are our own and not those of others. Our natural “identity card” is in the genes. Once our mother’s egg was fertilized by our father’s sperm, our genes became differentiated from theirs. We constitute ourselves as a new living entity similar to but different from that of our parents. Only a certain part of our cells preserve the identity of our mother.
Among all the information that is transmitted is also that of the system that identifies its own vital molecules with respect to those of any other living entity. These characteristic molecules of bacteria, fungi, viruses and all possible living beings can be of very different types. They are called “antigens.” The wonderful human immune system is capable of identifying foreign antigens that penetrate our body and generating an arsenal of its own components that are responsible for destroying their carriers.
If the invasion is by bacteria, or any other living alien organism, then they identify their foreign antigens, design the appropriate molecules to associate with them, and from there the life span of the invading organism is counted. The intruder can win only if our immune reaction is less efficient than the intruder’s harmful action or if the action of the intruder damages the immune system specifically. Viruses and the cells they infect are identified and killed in a similar way. AIDS, for example, originates from a virus that affects the immune system, and thus it is very difficult to overcome.
How, then, can a disease caused by a virus-like COVID-19 be defeated?
Essentially in two ways: the first is to combat and neutralize the effects of the virus on the diseased organism, which has been attacked. It is achieved with effective treatments. The second is to help identify and destroy the invading species by our own immune weapons. This can be achieved by “teaching” the immune system to do its job, but without the symptoms of the disease that can be fatal. That is “to get vaccinated” against the virus.
Luis Alberto Cabrera Montero holds a Doctorate Chemical Sciences. He is a Senior Researcher and Full Professor at the University of Havana. He is President of the Scientific Advisory Council of the University of Havana and is a Merit Member and Coordinator of Natural and Exact Sciences of the Academy of Sciences of Cuba. For a full biography, see http://www.academiaciencias.cu/en/node/674
You must be logged in to post a comment.